Patent application number | Description | Published |
20090169475 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS - Methods of imaging tissue of a mammal which expresses chymase include administering to the mammal an effective amount of a radiolabeled chymase inhibitor. Radiopharmaceuticals that may be used in diagnostic imaging and therapeutic treatment of disease characterized by expression of chymase have the structure of Formula I: | 07-02-2009 |
20090175794 | INHIBITORS OF CARBONIC ANHYDRASE IX - Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which is capable of binding the active catalytic site of CA-IX, and a radionuclide adapted for radioimaging and/or radiotherapy: | 07-09-2009 |
20100098633 | SELECTIVE SEPRASE INHIBITORS - Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by overexpression of seprase include complexes that contains a proline moiety and a radionuclide adapted for radioimaging and/or radiotherapy: | 04-22-2010 |
20100178246 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA - A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: | 07-15-2010 |
20100178247 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER - A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV. | 07-15-2010 |
20100183509 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF - Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin. | 07-22-2010 |
20140179902 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF - Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin. | 06-26-2014 |
20140341805 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF - A method of imaging a region in a subject includes administering to the subject a complex of a metal chelated to a compound, and obtaining an image of the region in the subject. | 11-20-2014 |
Patent application number | Description | Published |
20130034494 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS - Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: | 02-07-2013 |
20130216477 | METAL COMPLEXES OF POLY(CARBOXYL)AMINE-CONTAINING LIGANDS HAVING AN AFFINITY FOR CARBONIC ANHYDRASE IX - The present invention is directed to CA IX inhibitors that conform to Formula I where the substituents X, A, B, D, E, E′ and G are as defined above. | 08-22-2013 |
20130336888 | PSMA-TARGETED DENDRIMERS - A dendrimer conjugate according to Formula (I), or its pharmaceutically acceptable salt, or solvate thereof: and complexes of Formula I conjugates with metals radionuclides of elements such as rhenium, technetium, yttrium, lutetium and others to provide a complex for imaging tissues or for the radiotherapeutic treatment of cancer tissue. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed. | 12-19-2013 |
20140255306 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS - Compounds according to Formula I and Formula II are potent inhibitors of PSMA. | 09-11-2014 |
20150078998 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS - Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: | 03-19-2015 |